NCT05843383

Comparison of Ciprofol-based and Propofol-based Total Intravenous Anesthesia on Postoperative Quality of Recovery

Comparison of Ciprofol-based and Propofol-based Total Intravenous Anesthesia on Postoperative Quality of Recovery in Elderly Patients Undergoing Laparoscopic Surgery

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 280 (estimated)
• Sponsor: Xijing Hospital · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: Not accepted

Summary

Ciprofol is a novel 2,6-disubstituted phenol derivatives and is proved have much higher potency and tighter binding toward ɣ-aminobutyric acid type A (GABAA) receptor while maintaining a fast on-set and recovery time compared to propofol. Except lower incidence of hypotension and respiratory depression, it has no injection pain and infusion syndrome compared with propofol. There is no study to investigate overall postoperative functional recovery in patients receiving total intravenous anesthesia (TIVA) using ciprofol yet. However, according to study, early quality of recovery according to QoR-15 score is associated with one-month postoperative complications after elective surgery. Therefore, the purpose of this study is to determine whether there is any difference in the quality of postoperative recovery between ciprofol-based and propofol-based TIVA in elderly patients undergoing gastrointestinal surgery. The QoR-15 questionnaire score, pain, nausea/vomiting, and the frequency of complications are evaluated and compared between the two groups.

Conditions

• Anesthetics, Intravenous
• Postoperative Complications
• Hypnotics and Sedatives
• Postoperative Recovery

Interventions

Type	Name	Description
DRUG	Ciprofol	Ciprofol group will be started and maintained total intravenous anesthesia with ciprofol and remifentanil
DRUG	Propofol	Propofol group will be started and maintained total intravenous anesthesia with propofol and remifentanil

Timeline

• Start date: 2023-05-16
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2023-05-06
• Last updated: 2024-04-09

Locations

2 sites across 1 country: China